ScoreComparison
Company
Score
Quality
Valuation
Financial
Technical
Why is Iovance Biotherapeutics, Inc. ?
1
With a growth in Net Sales of 17.66%, the company declared Very Positive results in Sep 25
- The company has declared positive results for the last 4 consecutive quarters
- OPERATING CASH FLOW(Y) Highest at USD -323.14 MM
- NET SALES(HY) At USD 127.41 MM has Grown at 42.1%
- NET PROFIT(HY) Higher at USD -197.77 MM
2
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of -0.28%, its profits have risen by 4.3%
3
Reducing Promoter Confidence
- Promoters have decreased their stake in the company by -4.34% over the previous quarter and currently hold 8.52% of the company
- Promoters decreasing their stake may signify reduced confidence in the future of the business
4
Underperformed the market in the last 1 year
- Even though the market (S&P 500) has generated returns of 13.68% in the last 1 year, the stock has hugely underperformed and has generate negative returns of -0.28% returns
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Iovance Biotherapeutics, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Iovance Biotherapeutics, Inc. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Iovance Biotherapeutics, Inc.
3.31%
-0.49
112.78%
S&P 500
13.68%
0.71
19.28%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
202.05%
EBIT Growth (5y)
-16.38%
EBIT to Interest (avg)
-381.95
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.46
Sales to Capital Employed (avg)
0.14
Tax Ratio
0.86%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
80.60%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
2.37
EV to EBIT
-3.33
EV to EBITDA
-3.76
EV to Capital Employed
3.35
EV to Sales
5.47
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-100.63%
ROE (Latest)
-55.89%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Bearish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bullish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bearish
Mildly Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend13What is working for the Company
OPERATING CASH FLOW(Y)
Highest at USD -323.14 MM
NET SALES(HY)
At USD 127.41 MM has Grown at 42.1%
NET PROFIT(HY)
Higher at USD -197.77 MM
RAW MATERIAL COST(Y)
Fallen by -33.63% (YoY
EPS(Q)
Highest at USD -0.25
-2What is not working for the Company
CASH AND EQV(HY)
Lowest at USD 601.99 MM
DEBT-EQUITY RATIO
(HY)
Highest at -35.36 %
Here's what is working for Iovance Biotherapeutics, Inc.
Net Sales
At USD 127.41 MM has Grown at 42.1%
Year on Year (YoY)MOJO Watch
Near term sales trend is positive
Net Sales (USD MM)
Net Profit
Higher at USD -197.77 MM
than preceding 12 month period ended Sep 2025MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months
Net Profit (USD MM)
Operating Cash Flow
Highest at USD -323.14 MM
in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
EPS
Highest at USD -0.25
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (USD)
Raw Material Cost
Fallen by -33.63% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Iovance Biotherapeutics, Inc.
Cash and Eqv
Lowest at USD 601.99 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents
Debt-Equity Ratio
Highest at -35.36 %
in the last five Semi-Annual periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
